AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to kanamycin using DNA sequencing
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to amikacin using DNA sequencing
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting phenotypic resistance
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance using DNA sequencing
Number of subjects: 308
Study 28903892 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMoms intervention (in-person)
Number of subjects: 54
Study 28903892 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMoms intervention (remote)
Number of subjects: 54
Study 28903892 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study 28903892 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote intervention cost
Number of subjects: 54
Study 28903892 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention cost
Number of subjects: 54
Study 28903892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention adherence (SmartMoms)
Number of subjects: 54
Study 28903892 — intervention group
Group type: COMPARATOR
Intervention: Intervention adherence (Usual care)
Number of subjects: 54
Study 28903941 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin provision (IP) therapy
Number of subjects: 295
Study 28903941 — intervention group
Group type: COMPARATOR
Intervention: Insulin sensitization (IS) therapy
Number of subjects: 295
Study 28903943 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD19B at a dose of 300 μg/kg (3 μg/kg drug equivalents)
Number of subjects: 0
Study 28903943 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD19B in combination with rituximab at a dose of 100 μg/kg (1 μg/kg drug equivalents)
Number of subjects: 0
Study 28903943 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD19B
Number of subjects: 0
Study 28905294 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate cream (MAL) daylight photodynamic therapy (DL-PDT)
Number of subjects: 81
Study 28905323 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m²)
Number of subjects: 0
Study 28905323 — intervention group
Group type: EXPERIMENTAL
Intervention: panobinostat and 5-azacitidine
Number of subjects: 0
Study 28910851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic powder
Number of subjects: 44
Study 28911072 — intervention group
Group type: EXPERIMENTAL
Intervention: MSK-IMPACT genomic profiling
Number of subjects: 1932
Study 28911136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork ingestion (170 g) in the OB group
Number of subjects: 30
Study 28911136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork ingestion (170 g) in the NW group
Number of subjects: 30
Study 28911136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork ingestion (170 g) in the OW group
Number of subjects: 30
Study 28911136 — intervention group
Group type: COMPARATOR
Intervention: Basal MPS
Number of subjects: 30
Study 28911148 — intervention group
Group type: EXPERIMENTAL
Intervention: Young lean individuals (YL)
Number of subjects: 35
Study 28911148 — intervention group
Group type: EXPERIMENTAL
Intervention: Older lean individuals (OL)
Number of subjects: 35
Study 28911148 — intervention group
Group type: EXPERIMENTAL
Intervention: Older obese individuals (OO)
Number of subjects: 35
Study 28911148 — intervention group
Group type: COMPARATOR
Intervention: Young lean individuals (YL) vs Older lean individuals (OL)
Number of subjects: 35
Study 28911148 — intervention group
Group type: COMPARATOR
Intervention: Young lean individuals (YL) vs Older obese individuals (OO)
Number of subjects: 35
Study 28911148 — intervention group
Group type: COMPARATOR
Intervention: Older obese individuals (OO) vs Older lean individuals (OL)
Number of subjects: 35
Study 28911152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia preconditioning
Number of subjects: 13
Study 28911152 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia preconditioning
Number of subjects: 13
Study 28911152 — intervention group
Group type: EXPERIMENTAL
Intervention: HAAF induction
Number of subjects: 13
Study 28911517 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA Regulatory Approach
Number of subjects: 0
Study 28911517 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-h Algorithm for Rapid Diagnosis of MI
Number of subjects: 0
Study 28911922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg q12h daily combined with gemcitabine and cisplatin (SGC)
Number of subjects: 46
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant indocyanine green clearance rate using galactosyl (KGSA)
Number of subjects: 185
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hepatectomy liver failure definitions
Number of subjects: 185
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality rate
Number of subjects: 185
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity rate
Number of subjects: 185
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: Median hospital stay
Number of subjects: 185
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: Median ICU stay
Number of subjects: 185
Study 28912030 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day major complication and mortality rates
Number of subjects: 185
Study 28912187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy
Number of subjects: 0
Study 28912187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophic cardiomyopathy
Number of subjects: 0
Study 28912187 — intervention group
Group type: EXPERIMENTAL
Intervention: General pediatric cardiomyopathies
Number of subjects: 0
Study 28912376 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX 930 (recombinant ADAMTS-13) at doses of 5, 20, or 40 U/kg body weight
Number of subjects: 15
Study 28912629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple spinal manipulations administered in a single session
Number of subjects: 0
Study 28912629 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28912804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment
Number of subjects: 16
Study 28912956 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (2.0 g/day)
Number of subjects: 15
Study 28912956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28913744 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ADHD
Number of subjects: 392
Study 28913744 — intervention group
Group type: COMPARATOR
Intervention: Local normative (non-ADHD) comparison group
Number of subjects: 392
Study 28913922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximal tolerated dose (MTD)
Number of subjects: 230
Study 28913922 — intervention group
Group type: COMPARATOR
Intervention: HbF% values ≤20%
Number of subjects: 230
Study 28913922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 230
Study 28914600 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected fluorine 18
Number of subjects: 0
Study 28915798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Number of subjects: 90
Study 28915798 — intervention group
Group type: COMPARATOR
Intervention: Standard response assessment with RECISTv1.1 ceCT at 7 weeks
Number of subjects: 90
Study 28915825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention
Number of subjects: 135
Study 28915825 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 135
Study 28915844 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus Restriction
Number of subjects: 279
Study 28915844 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction
Number of subjects: 279
Study 28915862 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief education on pulse palpation focusing on evaluating rhythm regularity
Number of subjects: 205
Study 28915862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 205
Study 28915898 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMS
Number of subjects: 266
Study 28915898 — intervention group
Group type: COMPARATOR
Intervention: EMS
Number of subjects: 266
Study 28916584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low VWF levels (30-50 IU/dL)
Number of subjects: 126
Study 28916600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher white blood cell count (WBC)
Number of subjects: 4222
Study 28916600 — intervention group
Group type: COMPARATOR
Intervention: Lower white blood cell count (WBC)
Number of subjects: 4222
Study 28916602 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR measurements
Number of subjects: 0
Study 28916953 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg dexlansoprazole
Number of subjects: 104
Study 28916979 — intervention group
Group type: EXPERIMENTAL
Intervention: P4HB bioresorbable mesh
Number of subjects: 31
Study 28917612 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone level >2.5 mIU/L
Number of subjects: 1193
Study 28917612 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of thyroid antibodies
Number of subjects: 1193
Study 28917644 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS procedure
Number of subjects: 20
Study 28917648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer
Number of subjects: 32
Study 28917648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (physician choice: 5-FU/LV or capecitabine)
Number of subjects: 32
Study 28917648 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 32
Study 28917673 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n=27)
Number of subjects: 98
Study 28917673 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n=39)
Number of subjects: 98
Study 28917673 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (n=32)
Number of subjects: 98
Study 28917673 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT ≥15 ng/l (n=29) in Group B
Number of subjects: 98
Study 28917673 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP ≥550 pg/ml (n=10) in Group B
Number of subjects: 98
Study 28917674 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 154
Study 28917674 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 154
Study 28917674 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 154
Study 28917674 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 154
Study 28917674 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 154
Study 28918167 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI/%WL equal or higher than grade 3
Number of subjects: 84
Study 28918167 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-SGA classified as malnutrition
Number of subjects: 84
Study 28918167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low skeletal muscle mass
Number of subjects: 84
Study 28918167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle mass plus low muscle strength
Number of subjects: 84
Study 28918167 — intervention group
Group type: COMPARATOR
Intervention: Low muscle strength alone
Number of subjects: 84
Study 28918167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle mass in combination with low strength
Number of subjects: 84
Study 28918186 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-related limb lymphoedema present (109 patients)
Number of subjects: 431
Study 28918186 — intervention group
Group type: COMPARATOR
Intervention: No lymphoedema (322 patients)
Number of subjects: 431
Study 28918401 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work after ARDS
Number of subjects: 138
Study 28918401 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed return to work
Number of subjects: 138
Study 28918401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost earnings
Number of subjects: 138
Study 28918401 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare coverage
Number of subjects: 138
Study 28918414 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative online tool for peer review
Number of subjects: 0
Study 28918414 — intervention group
Group type: COMPARATOR
Intervention: Usual peer reviewer process
Number of subjects: 0
Study 28918441 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (200 μg)
Number of subjects: 16
Study 28918456 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day self-paced smartphone-delivered mindful eating intervention
Number of subjects: 104
Study 28919031 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) injection for fluorescence detection of sentinel lymph nodes (SLN)
Number of subjects: 30
Study 28919454 — intervention group
Group type: EXPERIMENTAL
Intervention: Abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination
Number of subjects: 0
Study 28919454 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28919776 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone (15 mg orally once daily)
Number of subjects: 0
Study 28921760 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide SNP genotyping
Number of subjects: 954
Study 28921872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg/day, orally, continuously
Number of subjects: 28
Study 28921872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 28
Study 28921907 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib and GSK2141795
Number of subjects: 0
Study 28922088 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane, 1 drop, 4 times daily for 6-8 weeks
Number of subjects: 72
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the internet to find information about health
Number of subjects: 3161
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the internet to find information about surgery
Number of subjects: 3161
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the internet to find specific information about anaesthesia
Number of subjects: 3161
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty searching for appropriate information about anaesthesia on the internet
Number of subjects: 3161
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of the web
Number of subjects: 3161
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the web on mobile devices
Number of subjects: 3161
Study 28922337 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking general practitioner or surgeon about information
Number of subjects: 3161
Study 28922466 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (continuous intravenous infusion)
Number of subjects: 189
Study 28923027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic principles access (APA)
Number of subjects: 120
Study 28923027 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive access (MIA)
Number of subjects: 120
Study 28923027 — intervention group
Group type: COMPARATOR
Intervention: Conventional access (CA)
Number of subjects: 120
Study 28923034 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 0
Study 28923034 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 28923060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D deficiency (<10 ng/ml)
Number of subjects: 960
Study 28923104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of enadenotucirev
Number of subjects: 17
Study 28923104 — intervention group
Group type: COMPARATOR
Intervention: Intratumoral (IT) injection of enadenotucirev (CRC only)
Number of subjects: 17
Study 28923290 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of Kaletra (lopinavir/ritonavir)
Number of subjects: 0
Study 28923290 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste stimuli including common excipients (ethanol, denatonium)
Number of subjects: 0
Study 28923290 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-phenotype relationships
Number of subjects: 0
Study 28923760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Disease Questionnaire
Number of subjects: 408
Study 28923760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 408
Study 28923760 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling Thermometer
Number of subjects: 408
Study 28923760 — intervention group
Group type: EXPERIMENTAL
Intervention: LASA Physical Activity Questionnaire (LAPAQ)
Number of subjects: 408
Study 28923760 — intervention group
Group type: EXPERIMENTAL
Intervention: BODEx index with LAPAQ added
Number of subjects: 408
Study 28923789 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4017
Number of subjects: 30
Study 28923789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28923845 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) <4 ng/L and cardiovascular risk factors <2
Number of subjects: 0
Study 28923845 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) with additional criteria of no change or a decrease between baseline and 2 h hs-cTnI
Number of subjects: 0
Study 28923845 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of hs-cTnI
Number of subjects: 0
Study 28923906 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 28924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg daily until cGVHD progression)
Number of subjects: 42
Study 28924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg daily)
Number of subjects: 42
Study 28925027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) drug levels <200 ng/ml or undetectable desethylchloroquine
Number of subjects: 305
Study 28925027 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires (MASRI <80% or MMAS-8 <6)
Number of subjects: 305
Study 28925027 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 305
Study 28925320 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic preoperative sinus CT checklist
Number of subjects: 57
Study 28925320 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative review (preimplementation)
Number of subjects: 57
Study 28925320 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimplementation review with checklist
Number of subjects: 57
Study 28925785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy after four cycles (FCR4)
Number of subjects: 52
Study 28925785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy at end of treatment (EOT)
Number of subjects: 52
Study 28925785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy
Number of subjects: 52
Study 28926513 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg phytoSERM
Number of subjects: 18
Study 28926513 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg phytoSERM
Number of subjects: 18
Study 28926513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28927372 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate regular medication
Number of subjects: 881
Study 28927372 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more potentially inappropriate medications
Number of subjects: 881
Study 28927372 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication needing surveillance according to NORGEP-NH
Number of subjects: 881
Study 28927372 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of psychotropic drugs
Number of subjects: 881
Study 28927372 — intervention group
Group type: COMPARATOR
Intervention: Potentially inappropriate regular medication (females)
Number of subjects: 881
Study 28927372 — intervention group
Group type: COMPARATOR
Intervention: Three or more concomitant psychotropic medications (females)
Number of subjects: 881
Study 28927372 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of multiple psychoactive drugs
Number of subjects: 881
Study 28927395 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker monitoring for signs of HRPB
Number of subjects: 7050
Study 28927395 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification based on signs and symptoms of HRPB
Number of subjects: 7050
Study 28927712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 111
Study 28927712 — intervention group
Group type: COMPARATOR
Intervention: No Rufinamide
Number of subjects: 111
Study 28928173 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-TB treatment
Number of subjects: 268
Study 28928173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis
Number of subjects: 268
Study 28928706 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-driven NMES-robotic arm
Number of subjects: 0
Study 28928706 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical treatments
Number of subjects: 0
Study 28928789 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) treatment during hospitalization
Number of subjects: 524
Study 28930079 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women with excess EAT
Number of subjects: 82
Study 28930079 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected women
Number of subjects: 82